Hepatitis C virus (HCV) affects approximately 3% of the world population. The current standard of care for treatment of HCV is a combination of pegylated interferon and ribavirin. Approximately 10% of patients will stop treatment and 30% of patients require dose reduction because of side effects. For genotype 1 HCV-infected patients, only 40% of patients will achieve undetectable viral load 26 weeks posttreatment. This review suggests that combinations of DAA are a promising area of research with a high success rate.
Clinical trials show that future HCV therapy could be personalised, achieve higher success rates with decreased adverse incidents.